Actinium Pharmaceuticals, Inc (ATNM) Live Share Price, Invest From India

Actinium Pharmaceuticals, Inc Stock Performance

as on July 14, 2026 at 2:15 pm IST

Day's Low
Day's High
$0.90
Day's Price Range
$0.97
$0.91
1.10%
Downside
6.59%
Upside
52 Week's Low
52 Week's High
$0.90
52-Week Price Range
$1.89
$0.91
1.09%
Downside
107.69%
Upside

Actinium Pharmaceuticals, Inc share price movements today

Previous Close: $0.93
Open: $0.92
Volume: 696.8K
Day's Low - High: $0.90 - $0.97
52 Week Low - High: $0.90 - $1.89

Actinium Pharmaceuticals, Inc Historical Returns

1 Month Return: -10.4 %
3 Month Return: -17.73 %
1 Year Return: -42.36 %
3 Year Return: -87.05 %
5 Year Return: -86.65 %

Actinium Pharmaceuticals, Inc Stock Fundamentals & Key Indicators

Check Actinium Pharmaceuticals, Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$29.2M

EPS (TTM)

-0.91

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-25.3M

Revenue (TTM)

90.0K

Profit Margin

0.00%

Return On Equity TTM

-167.66%

Actinium Pharmaceuticals, Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Actinium Pharmaceuticals, Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Actinium Pharmaceuticals, Inc	BUY	$29.2M	-86.65%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.9B	69.11%	75.25	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$123.2B	142.69%	28.82	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$69.7B	14.12%	16.24	29.65%	0.54%

Stock Returns calculator for Actinium Pharmaceuticals, Inc Stock including INR - Dollar returns

The Actinium Pharmaceuticals, Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Actinium Pharmaceuticals, Inc investment value today

Current value as on today

₹64,430

Returns

-₹35,570

(-35.57%)

Returns from Actinium Pharmaceuticals, Inc Stock

-₹42,038 (-42.04%)

Dollar Impact

₹6,468 (+6.47%)

Analyst Recommendation on Actinium Pharmaceuticals, Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Actinium Pharmaceuticals, Inc. Average target price of $5

Actinium Pharmaceuticals, Inc Share Price Target

Get share price movements and forecasts by analysts on Actinium Pharmaceuticals, Inc.

What analysts predicted

81.8%UPSIDE

Target Price

Current Price

$0.91

Analyzed by

12 Analysts

Target

$5.00

Actinium Pharmaceuticals, Inc target price $5, a slight upside of 81.8% compared to current price of $0.91. According to 12 analysts rating.

Indian Investors' Interest in Actinium Pharmaceuticals, Inc Stock

Search interest for Actinium Pharmaceuticals, Inc Stock has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Time period: June 14, 2026 to July 14, 2026

Change:-47% versus previous 30 day period

Actinium Pharmaceuticals, Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	-	-	-	0	-	-	0	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-10	-9	-12	-12	-7	-16	-7	-5	-6	-5
EBITDA	-9	-8	-11	-11	-6	-15	-6	-4	-5	-5
Interest Expense	0	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-9	-8	-11	-11	-6	-15	-6	-5	-5	-5
Income Tax Expense	0	0	-	-11	-	-	-	-	-	-
Net Income	-9	-8	-11	-11	-6	-15	-6	-5	-5	-5
Net Profit Margin	-11511.11%	0.00%	0.00%	0.00%	-821.23%	0.00%	0.00%	-5701.11%	0.00%	0.00%

Actinium Pharmaceuticals, Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	0	1	1	0	-	0
Gross Profit	0	0	0	0	0	0	1	0	0	0
Operating Income	-26	-26	-23	-22	-22	-24	-34	-51	-42	-36
EBITDA	-26	-26	-23	-21	-21	-24	-32	-48	-37	-33
Interest Expense	0	0	0	-	-	0	1	-	-	-
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-24	-26	-23	-21	-22	-24	-33	-48	-38	-33
Income Tax Expense	0	0	0	0	0	0	-1	0	-	-
Net Income	-24	-26	-23	-21	-22	-24	-33	-48	-38	-33
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-3571.54%	-2165.56%	-3205.53%	-60269.14%	0.00%	-37652.22%

Actinium Pharmaceuticals, Inc Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-8	-11	-11	-6	-15	-6	-5	-5	-5
Operating Cash Flow	-7	-7	-11	-5	-7	-5	-6	-5	-5
Investing Cash Flow	0	-	-	-	-	-	-	0	0
Financing Cash Flow	14	9	4	0	0	0	0	0	0
Change in Cash	7	1	-7	-5	-7	-5	-6	-5	-5

Actinium Pharmaceuticals, Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-26	-23	-21	-22	-24	-33	-48	-38	-33
Operating Cash Flow	-21	-20	-21	-21	-20	8	-47	-33	-24
Investing Cash Flow	0	0	0	0	0	0	0	0	0
Financing Cash Flow	18	16	17	76	35	23	14	29	0
Change in Cash	-3	-3	-4	54	14	31	-32	-3	-24

Insights on Actinium Pharmaceuticals, Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -5.94M → -5.52M (in $), with an average increase of 7.6% per quarter
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 16.5% return, outperforming this stock by 57.3%
NO EFFECT
Against Peers
In the last 3 years, Actinium Pharmaceuticals, Inc has experienced a drawdown of -86.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 79.2%
NEGATIVE IMPACT
Price Dip
In the last 7 days, ATNM stock has moved down by -11.4%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 810.0K → 90.0K (in $), with an average decrease of 88.9% per quarter

About Actinium Pharmaceuticals, Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Organisation	Actinium Pharmaceuticals, Inc
Headquarters	100 Park Avenue, New York, NY, United States, 10017
Industry	Biotechnology
CEO	Mr. Sandesh C. Seth M.B.A., M.S.
E-voting on shares	Click here to vote

Key Management of Actinium Pharmaceuticals, Inc

Name	Title
Mr. Sandesh C. Seth M.B.A., M.S.	CEO, Principal Financial Officer & Chairman
Dr. Paul Diamond Esq., Ph.D.	Vice President of Patent & Legal Counsel
Ms. Lynn M. Bodarky M.B.A.	Chief Business Officer
Dr. Steffen Heeger M.D., M.Sc., Ph.D.	Chief Medical Officer
Dr. Madhuri Vusirikala M.D.	Vice President of Clinical Development BMT & Cellular Therapy

FAQs

What is Actinium Pharmaceuticals, Inc share price today?

Actinium Pharmaceuticals, Inc share price today is $0.91 as on July 14, 2026 at 8:45 am IST at the close of the market. Actinium Pharmaceuticals, Inc share today touched a day high of $0.97 and a low of $0.90.

What is the 52 week high and 52 week low for Actinium Pharmaceuticals, Inc share?

Actinium Pharmaceuticals, Inc share touched a 52 week high of $1.89 on July 23, 2025 and a 52 week low of $0.90 on July 13, 2026. Actinium Pharmaceuticals, Inc stock price today i.e. July 14, 2026 at 8:45 am IST is closed at $0.91,which is 51.85% down from its 52 week high and 1.10% up from its 52 week low.

What is Actinium Pharmaceuticals, Inc's market capitalisation today?

Actinium Pharmaceuticals, Inc market capitalisation is $0.00T as on July 14, 2026 at 8:45 am IST.

How to invest in Actinium Pharmaceuticals, Inc Stock (ATNM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Actinium Pharmaceuticals, Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Actinium Pharmaceuticals, Inc Shares that will get you 1.6484 shares as per Actinium Pharmaceuticals, Inc share price of $0.91 per share as on July 14, 2026 at 8:45 am IST.

What is the minimum amount required to buy Actinium Pharmaceuticals, Inc Stock (ATNM) from India?

Indian investors can start investing in Actinium Pharmaceuticals, Inc (ATNM) shares with as little as ₹95.615 or $1 (as of July 14, 2026 at 4:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.15 in Actinium Pharmaceuticals, Inc stock (as per the Rupee-Dollar exchange rate as on July 14, 2026 at 4:40 pm IST). Based on Actinium Pharmaceuticals, Inc share’s latest price of $0.91 as on July 14, 2026 at 8:45 am IST, you will get 10.9890 shares of Actinium Pharmaceuticals, Inc. Learn more about fractional shares .

What are the returns that Actinium Pharmaceuticals, Inc has given to Indian investors in the last 5 years?

Actinium Pharmaceuticals, Inc stock has given -86.65% share price returns and 27.79% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?